* Maximum benefit is $240 off, up to $20 off each prescription (up to 12 prescriptions),
depending on your out-of-pocket costs. Not valid for patients participating in Medicare,
Medicaid, government (public insurance) programs, or any private payor in the state
of Massachusetts and where prohibited by law.
AMBIEN CR is indicated for the treatment of insomnia characterized by difficulties
with sleep onset and/or sleep maintenance.
AMBIEN® (zolpidem tartrate) is indicated for the short-term treatment
of insomnia characterized by difficulties with sleep initiation.
IMPORTANT SAFETY INFORMATION
In elderly or debilitated patients, or in patients with hepatic insufficiency or
dysfunction, the recommended dose of AMBIEN CR is 6.25 mg and the recommended dose
of AMBIEN is 5 mg. These patients should be closely monitored.
AMBIEN CR and AMBIEN both have rapid onset of action; therefore, patients should
ingest right before going to bed and when ready for sleep. To avoid residual effects,
patients should not take AMBIEN CR or AMBIEN unless they are prepared to get a full
night’s sleep (7 to 8 hours). Until they know how it will affect their physical
or mental performance upon awakening, patients should not drive or operate hazardous
machinery after taking AMBIEN CR, AMBIEN, or any other sleep medication. Complex
behaviors such as somnambulism, including driving or eating while not fully awake,
with amnesia for the event, as well as abnormal behaviors such as being more outgoing
or aggressive than normal, confusion, agitation, and hallucinations may occur. AMBIEN
CR or AMBIEN should not be taken with alcohol as they may increase these abnormal
behaviors. Discontinuation of AMBIEN CR or AMBIEN should be strongly considered
for patients reporting such complex behaviors. Angioedema may occur in patients
taking AMBIEN CR or AMBIEN and in rare cases may be fatal. Patients who develop
angioedema should not be rechallenged. In primarily depressed patients, worsening
of depression, including risk of suicidal thoughts or actions, including completed
suicides, have been reported. The most commonly observed adverse effects in controlled
clinical trials of AMBIEN CR were headache, somnolence, and dizziness. During short-term
treatment with AMBIEN, the most commonly observed adverse effects in controlled
clinical trials were drowsiness, dizziness, and diarrhea. Because individuals with
a history of addiction or substance abuse are at increased risk of habituation and
dependence, they should be under careful surveillance when receiving
AMBIEN CR, AMBIEN, or any other hypnotic. Both AMBIEN CR and AMBIEN are Schedule
IV controlled substances. Sedative hypnotics have produced withdrawal symptoms following
abrupt discontinuation.
Please refer to the full prescribing information for AMBIEN CR.
Please refer to the full prescribing information for AMBIEN.